Novel interventional study to progress multi-cancer, early-detection test into clinical practice

GRAIL (CA, USA) has announced the launch of a prospective, interventional study seeking to advance its multi-cancer, early-detection test into clinical practice. The healthcare company GRAIL (CA, USA) has announced the launch of an interventional, multi-center study, entitled PATHFINDER, which ultimately aims to advance GRAIL’s multi-cancer, early-detection test into clinical practice. It is well established that the earlier detection of cancer is associated with improved prognosis, treatment success and survival rates. However, there are no guideline-recommended screening procedures currently available for many of the deadliest cancers. GRAIL’s multi-cancer, early-detection test employs methylation-based technology, which targets the most informative regions of...